(Total Views: 512)
Posted On: 01/28/2021 10:51:52 AM
Post# of 153903
Nelson,
I would adjust your numbers, as NASH will be an $80B market for any who are successful and Price/revenue should be between 5x and 10x.
No current successful therapeutics in NASH, so 75% for Cytodyn is wholly reasonable. If we use the rest of your revenue guesstimates:
NASH 50% of $80B = $60B
Covid $2.5B
Cancer $5.4 B
HIV $6B
Total sales =$79.4B (round to 80 for ease)
5 x 80B is 400B
10 x 80B is 800 B
Fully diluted shares (outstanding, warrants and authorized) is close to 800M
Share price is 500-1000.
Crazy stuff, which is why most of us avoid going to frequently into this rabbit hole.
Dizzying.
I would adjust your numbers, as NASH will be an $80B market for any who are successful and Price/revenue should be between 5x and 10x.
No current successful therapeutics in NASH, so 75% for Cytodyn is wholly reasonable. If we use the rest of your revenue guesstimates:
NASH 50% of $80B = $60B
Covid $2.5B
Cancer $5.4 B
HIV $6B
Total sales =$79.4B (round to 80 for ease)
5 x 80B is 400B
10 x 80B is 800 B
Fully diluted shares (outstanding, warrants and authorized) is close to 800M
Share price is 500-1000.
Crazy stuff, which is why most of us avoid going to frequently into this rabbit hole.
Dizzying.
(5)
(0)
